Ian Watkins - Mallinckrodt Public Insider

MNK -- USA Stock  

USD 29.75  0.07  0.24%

  SVP
Mr. Ian J. Watkins is Chief Human Resource Officer of Mallinckrodt Public Limited Company. He has executive responsibility for organizational development, effectiveness and sustainability, talent acquisition, total rewards, and human resources systems and service delivery. He is also responsible for supporting the Board of Directors in their governance activities related to executive compensation, talent and succession management. Mr. Watkins joined Covidiens Pharmaceuticals business in September 2012 as the Chief Human Resources Officer. Mr. Watkins served as Vice President, Global Human Resources at Synthes, Inc. from June 2007 to September 2012, which was acquired by Johnson Johnson. Mr. Watkins served as Senior Vice President, Human Resources from 2003 to 2006 for Andrx Corporationrationration, which is now part of Allergan, Inc.
Age: 54  SVP Since 2016      
44 17 8463 6700  http://www.mallinckrodt.com

Ian Watkins Latest Insider Activity

Management Efficiency

The company has Return on Asset of 2.31 % which means that on every $100 spent on asset it made $2.31 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 29.84 % implying that it generated $29.84 on every 100 dollars invested.
The company has 6.36 B in debt with debt to equity (D/E) ratio of 98.1 . This implies that the company may be unable to create cash to meet all of its financial commitments. Mallinckrodt Public Limited Company has Current Ratio of 2.22 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Found 3 records

SVP Since

Judy JoiceDURECT Corporation
2014
John MaslowskiFibrocell Science
2017
Sherry KorczynskiEagle Pharmaceuticals
N/A

Entity Summary

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company is based in Staines-Upon-Thames, the United Kingdom. Mallinckrodt Public operates under Drug Manufacturers - Specialty Generic classification in USA and traded on BATS Exchange. It employs 00 people.Mallinckrodt Public Limited Company (MNK) is traded on BATS Exchange in USA. It is located in IRELAND and employs 3,900 people. Mallinckrodt Public is listed under Pharmaceutical Products category by Fama And French industry classification.

Mallinckrodt Public Leadership Team

Gary Phillips, Senior Vice President and Chief Strategy Officer
Steven Romano, Executive Vice President and Chief Scientific Officer
Mark Casey, General Counsel
JoAnn Reed, Independent Director
Virgil Thompson, Independent Director
Diane Gulyas, Independent Director
Joseph Zaccagnino, Independent Director
Paul Carter, Independent Director
David Carlucci, Independent Director
Frank Scholz, Sr. VP of Global Operations
David Norton, Independent Director
Hugh ONeill, Sr. VP and President of Autoimmune and Rare Diseases
Martin Carroll, Independent Director
Steve Romano, Senior Vice President Chief Scientific Officer
Mark Trudeau, CEO and President Director and Member of Portfolio Committee
Kneeland Youngblood, Independent Director
Meredith Fischer, Senior Vice President - Communications and Public Affairs
Terrance Carlson, Senior Vice President and General Counsel - Interim
Ian Watkins, Chief HR Officer and Sr. VP
Melvin Booth, Independent Chairman of the Board
Raymond Furey, Senior Vice President Chief Compliance Officer
Angus Russell, Independent Director
Ronald Lloyd, Executive Vice President and President - Hospital Therapies
Karen Sheehy, Chief Compliance Officer
Matthew Harbaugh, CFO and Sr. VP
MichaelBryant Hicks, General Counsel
Anne Whitaker, Independent Director

Stock Performance Indicators

Did you try this?

Run Portfolio Reporting Now

   

Portfolio Reporting

Create custom reports across your portfolios and generate quick suggestion pitch
All  Next Launch Portfolio Reporting

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try CEO Directory module to screen ceos from public companies around the world.
Search macroaxis.com